Brentuximab Vedotin
CAS: 914088-09-8
Description:
Brentuximab vedotin is an antibody-drug conjugate (ADC) used to treat hematologic cancers. It combines the anti-CD30 monoclonal antibody, brentuximab, with the cytotoxic drug vedotin (monomethyl auristatin E, MMAE). The antibody targets CD30, a protein found on tumor cells, and delivers MMAE directly to the cancer cells, causing their death. It is mainly used to treat Hodgkin lymphoma, anaplastic large cell lymphoma, and other CD30-positive cancers.
Key Features:
- CD30 Targeting: Brentuximab binds specifically to CD30 on tumor cells, enabling targeted drug delivery.
- Cytotoxic Agent (MMAE): MMAE disrupts microtubules, leading to cancer cell death.
- Linker Technology: The stable linker between brentuximab and MMAE ensures the drug reaches cancer cells efficiently.
Applications:
- Cancer Treatment: Targets and destroys CD30-positive cancer cells, particularly in Hodgkin lymphoma and anaplastic large cell lymphoma.
- Targeted Therapy: Delivers MMAE directly to cancer cells, reducing side effects and sparing healthy tissue.
- Monoclonal Antibody Therapy: Provides a targeted and effective treatment option for patients with CD30-expressing tumors.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.